Which factors should be considered in chemotherapy regimen selection for mantle cell lymphoma (MCL)?

Updated: Mar 15, 2019
  • Author: Muhammad Rashid Abbasi, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Considerations in regimen selection are as follows:

  • Therapy with single alkylating agents may be preferable for elderly patients or for those with serious comorbid medical problems who require therapy for lymphoma

  • First-line therapy is with hyper-CVAD, with or without rituximab; or with bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone

  • Hyper-CVAD with rituximab (R–hyper-CVAD) has shown very encouraging  results but is intensive and relatively toxic

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!